Loxo Oncology To Present At Upcoming Investor Conferences

Published: Feb 04, 2015

STAMFORD, Conn., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced that Joshua H. Bilenker, M.D., Chief Executive Officer will present a corporate overview at two upcoming conferences.

Details of the conferences are as follows:

2015 Leerink Global Healthcare Conference, February 11, 2015 at 3:05 pm ET, The Waldorf Astoria Hotel, New York, NY
Cowen & Co. 35^th Annual Health Care Conference, March 2, 2015 at 4:10 pm ET, The Boston Marriott Copley Place, Boston MA

Live webcasts of the presentations will be available at http://ir.loxooncology.com/.

About Loxo Oncology

Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. We partner with leaders in academia and industry, allowing our management team to focus on clinical-regulatory execution in well-defined patient populations. www.loxooncology.com.

Contacts

Company:

Jacob S. Van Naarden

Vice President, Corporate Development and Strategy

jake@loxooncology.com

Investors:

Peter Rahmer

The Trout Group, LLC

646-378-2973

prahmer@troutgroup.com

Media:

Karen Sharma